pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
630
stories
Apr 30, 26
STAT+: Hair-raising trial results, and Servier’s M&A wishlist
stat
Apr 30, 26
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
endpoints
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
STAT+: Five-way obesity drug is super effective — in mice
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 30, 26
Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
endpoints
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 29, 26
STAT+: A patent win for Pfizer and BridgeBio
stat
Apr 28, 26
STAT+: FDA launches effort to speed up clinical trials, using AI
stat
Apr 28, 26
Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
stat
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
stat
Apr 28, 26
Lilly strikes second partnership this year for recombinase-based gene editing
endpoints
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 28, 26
STAT+: Eli Lilly enlists AI startup for next-generation gene editors
stat
Apr 27, 26
Lilly to buy startup Ajax in bid for a better JAK drug
biopharma dive
Apr 27, 26
STAT+: Astellas retries XLMTM gene therapy after deaths
stat
Apr 27, 26
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
endpoints
Apr 25, 26
Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77
stat
Apr 24, 26
STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
stat
Apr 24, 26
STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment
stat
Apr 24, 26
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
biopharma dive
Apr 24, 26
Growing use of guest editors has turned some journals into a ‘playground of bad science’
stat
Apr 23, 26
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
stat
Apr 23, 26
FDA approves Regeneron’s hearing loss gene therapy
biopharma dive
Apr 23, 26
Heart’s beat may help it beat cancer, mouse research suggests
stat
Apr 23, 26
Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
biopharma dive
Apr 23, 26
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
biopharma dive
Dec 23, 25
Fierce Biotech Layoff Tracker 2026: Enlivex excises 60%; Eyepoint halves headcount
fiercebiotech
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series A
fiercebiotech
← prev
page 21 of 21
next →
